Skip to main content
As published for the week of Monday, November 23, 2015

  • Cover Story: More with less

    How Merck Serono's new R&D chief is shaping the pipeline

    By Erin McCallister, Senior Editor

    With 16 months under his belt as the new head of global R&D for Merck KGaA's biopharmaceuticals division, Luciano Rossetti has pruned the pipeline, accelerated the unit's cancer immunotherapy efforts and revived one late-stage program. Evidence of whether he's put the pipeline on solid footing could come as early as next half, when many of these programs start to read out.

    Rossetti, formerly SVP of late stage development at Merck & Co. Inc., came on board in July 2014. He replaced interim head of R&D Belén Garijo, who resumed her position as president and CEO of Merck's biopharma division.

    Full Article

Money Raised in 2015

Last week, the biotech industry raised $149 million, bringing to $100.2 billion the total raised year-to-date. In 2014, a total of $54.9 billion was raised, including $21.6 billion in debt, $11.1 billion in follow-ons, $4 billion in PIPEs and other equity, $9.1 billion in IPOs, and $9.2 billion in venture capital. Totals include overallotments and warrants, and are rounded to the nearest millions.

Subscribe Now
Free Trial